353 / 1228
Type A uncertainty
TG-43 U1* suggests that enough histories, N, should be used to ensure that dosimetry
l h l i
i i
resu ts ave re at ve uncerta nt es <2% at r<5 cm
AAPM/ESTRO** recommendations are MC Type A uncertainties (k=1)<0.1% for
distances < 5 cm and Type A uncertainties (k=1)<0.2% for distances <10cm
TG-138 (AAPM/ESTRO)*** suggests MC type A<0 1% when feasible
.
* Rivard et al., 2004. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for
brachytherapy dose calculations. Med. Phys. 31(3), p.633.
** Perez Calatayud et al
2012 Dose calculation for photon emitting brachytherapy sources with
-
.,
.
-
average energy higher than 50 keV: report of the AAPM and ESTRO. Med. Phys. 39(5), p.2904
*** DeWerd et al., 2011. A dosimetric uncertainty analysis for photon-emitting brachytherapy sources:
report of AAPM Task Group No. 138 and GEC-ESTRO. Med. Phys. 38(2), pp. 782